(Q40202733)

18 September 2017

title

Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma (English)

1 reference

18 September 2017

Haritunians T

1

1 reference

18 September 2017

Mori A

2

1 reference

18 September 2017

O'Kelly J

3

1 reference

18 September 2017

Luong QT

4

1 reference

18 September 2017

Giles FJ

5

1 reference

18 September 2017

Koeffler HP

6

1 reference

18 September 2017

publication date

30 November 2006

1 reference

18 September 2017

1 reference

18 September 2017

volume

21

1 reference

18 September 2017

issue

2

1 reference

18 September 2017

page(s)

333-339

1 reference

Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4

18 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404471

G1 phase progression: cycling on cue

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404471

Synergistic effect of targeting mTOR by rapamycin and depleting ATP by inhibition of glycolysis in lymphoma and leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404471

Regulation of translation initiation by FRAP/mTOR

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404471

The Akt-mTOR tango and its relevance to cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404471

Tor signalling in bugs, brain and brawn

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404471

Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404471

Antileukemic activity of rapamycin in acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404471

Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404471

Effects of a combined treatment with mTOR inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404471

Vitamin D2 analog 19-nor-1,25-dihydroxyvitamin D2: antitumor activity against leukemia, myeloma, and colon cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404471

Mechanism by which mammalian target of rapamycin inhibitors sensitize multiple myeloma cells to dexamethasone-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404471

Combination of imatinib with rapamycin or RAD001 acts synergistically only in Bcr-Abl-positive cells with moderate resistance to imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404471

Current treatment approaches for mantle-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404471

Chemotherapy with rituximab followed by high-dose therapy and autologous stem cell transplantation in patients with mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404471

Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: res

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404471

Biology and management of mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404471

The phosphatidylinositol 3-Kinase AKT pathway in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404471

mTOR-targeted therapy of cancer with rapamycin derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404471

Mantle cell lymphoma: established therapeutic options and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404471

Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404471

AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404471

Rapamycin stimulates apoptosis of childhood acute lymphoblastic leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404471

Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404471

A rapamycin derivative (everolimus) controls proliferation through down-regulation of truncated CCAAT enhancer binding protein {beta} and NF-{kappa}B activity in Hodgkin and anaplastic large cell lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404471

Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404471

4E-binding proteins, the suppressors of eukaryotic initiation factor 4E, are down-regulated in cells with acquired or intrinsic resistance to rapamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404471

Anti-CD20-based therapy of B cell lymphoma: state of the art.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404471

Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404471

Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404471

Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404471

NF-kB in development and progression of human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404471

Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404471

Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404471

Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404471

Clustering of breakpoints on chromosome 11 in human B-cell neoplasms with the t(11 ; 14) chromosome translocation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404471

Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404471

7 January 2021

Mantle cell lymphoma: a retrospective study of 121 cases

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404471

7 January 2021

Concurrent administration of high-dose chemotherapy and rituximab is a feasible and effective chemo/immunotherapy for patients with high-risk non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404471

7 January 2021

Low-dose weekly paclitaxel for recurrent or refractory aggressive non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404471

7 January 2021

Identifiers

DOI

10.1038/SJ.LEU.2404471

1 reference

Dimensions Publication ID

18 September 2017

1037850468

0 references

1 reference